joimax® GmbH, Karlsruhe, founded in 2001, is a German company with more than 60 employees in Germany and a subsidiary in Irvine, CA, with currently 15 employees. The company is the leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery.
With TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® RT (e.g. for rhizotomy); MultiZYTE® SI for the treatment of Sacroiliac Joint Syndrome and with EndoLIF® and Percusys® for minimally-invasive endoscopic assisted stabilizations proven endoscopic systems are provided that together cover a variety of indications.
Surgeons operate through a single small incision under general or local anaesthetic via tissue and muscle sparing through natural openings into the spinal canal (e.g. intervertebral foramen). To date, numerous studies and applications have demonstrated the advantage and reliability of these systems. Until now, there have been performed more than 300.000 surgeries in more than 900 centers in about 50 countries. The main markets are Europe, Asia and USA.
joimax® established a dynamic 3-step-concept for surgeons to learn these endoscopic minimally invasive surgical techniques. Up to now, more than 3.200 surgeons have been trained in basic and advanced courses especially to learn these methods. Starting in 2017 joimax® additionally offers also workshops in pain therapy.
The novel systems consist of a complete endoscopic full HD-visualization system, specially designed scopes, a shaver-drill system, a multiradiofrequency unit, special surgical instruments and disposables as well as a PC-based patient documentation device. The latest development integrates an electromagnetic navigation technology called Intracs® into the full endoscopic system. It enables the surgeon to navigate any instrument tip right to the target point. To date, joimax® holds more than 150 patents and trademarks. Further registrations are to follow.
Since 2008, the demand for such endoscopic spinal surgeries has increased significantly and has reached a market penetration rate of nearly 10% (Germany ~12%, Europe ~5%, Korea ~30%, USA ~2%). Since 2008, joimax® revenues show a CAGR (compound annual growth rate) of more than 30%, in some regions even more than 50% p. a.